Ultralife Corporation (NASDAQ: ULBI) reported operating income of
$1.1 million on revenue of $26.8 million for the second quarter
ended June 30, 2021. For the second quarter of 2020, the Company
reported operating income of $2.3 million on revenue of $28.6
million.
“Ultralife’s end-market diversification strategy
continues to serve us well. For the second quarter, sales increased
sequentially 3% from the first quarter as our oil & gas
revenues rebounded, growing 49% year over year. Medical sales
abated from last year’s COVID-related demand spike yet were above
pre-pandemic levels, and sales from government/defense customers
were soft relative to last year’s strong shipment flows,” said
Michael D. Popielec, President and Chief Executive Officer. “Given
our solid liquidity position, we increased investments in capex and
critical engineering resources to support new contracts and
completion of transformational new products. Although these
investments weighed on operating and net income year-over-year
comparisons, sequential EPS grew 20% on the strength of gains in
commercial sales.”
Added Mr. Popielec, “Supply chains and logistics
continue to be the source of operational challenges, delaying some
shipments and increasing freight costs, and clouding our visibility
for the second half of the year. Nevertheless, activity in our end
markets remains high and our goal is to continue improving our
financial performance each quarter. We remain focused on executing
near-term growth initiatives and developing long-term growth
opportunities while adhering to our proven and profitable business
model.”
Second Quarter 2021 Financial Results
Revenue was $26.8 million, a decrease of $1.8
million, or 6.3%, compared to $28.6 million for the second quarter
of 2020. Overall, commercial sales decreased 1.0% and
government/defense sales decreased 13.2% from the 2020 period.
Battery & Energy Products declined 4.8% to $22.9 million,
compared to $24.0 million last year, with a 48.6% increase in oil
& gas market sales and a 23.2% increase in 9-Volt sales offset
by a 27.9% decrease in medical battery sales and a 12.7% decrease
in government/defense sales. Communications Systems sales decreased
13.9% to $3.9 million compared to $4.5 million for the same period
last year, primarily due to 2020 shipments of vehicle
amplifier-adaptor systems to support the U.S. Army’s Network
Modernization initiatives completing the delivery orders announced
in October 2018. During the 2021 second quarter, increased lead
times on components from suppliers and other COVID-19 related
logistics matters resulted in delays in our shipments to future
periods. We estimate that the delayed shipments adversely impacted
revenue for the 2021 second quarter by approximately $1.5
million.
Gross profit was $7.3 million, or 27.1% of
revenue, compared to $8.0 million, or 27.9% of revenue, for the
same quarter a year ago. Battery & Energy Products’ gross
margin was 26.3%, compared to 25.1% last year, as a result of
favorable sales product mix and lower scrap and rework on new
products transitioning to high volume production. Communications
Systems gross margin was 32.1%, compared to 42.8% last year,
primarily due to the favorable sales mix in 2020 of the vehicle
amplifier-adaptor systems for the U.S. Army.
Operating expenses were $6.2 million compared to
$5.7 million last year, representing an increase of 9.0%, primarily
relating to our continued investment in engineering resources for
new product development, including resources dedicated to the
Conformal Wear Battery IDIQ contract awarded in May 2021. Operating
expenses were 23.1% of revenue compared to 19.8% of revenue for the
year-earlier period.
Operating income was $1.1 million compared to
$2.3 million last year, and operating margin was 4.1% compared to
8.0% last year. We estimate that delayed shipments resulting from
supply chain and other COVID-19 related logistics matters adversely
impacted operating income for the 2021 second quarter by
approximately $0.5 million.
Net income was $0.8 million or $0.05 per diluted
share using the U.S. statutory tax rate, compared to net income of
$1.7 million or $0.10 per diluted share for the second quarter of
2020. Adjusted EPS was $0.06 on a diluted basis for the second
quarter of 2021, compared to $0.13 for the 2020 period. Adjusted
EPS excludes the provision for deferred taxes which primarily
represents non-cash charges of $.2 million for U.S. taxes which
will be fully offset by net operating loss carryforwards and other
tax credits for the foreseeable future. We estimate that delayed
shipments resulting from supply chain and other COVID-19 related
logistics matters adversely impacted Adjusted EPS for the 2021
second quarter by approximately $0.03.
During the second quarter of 2021, our
cash-on-hand increased by 15.9% to $15.8 million and our debt was
reduced by 36.6% to $0.7 million.
See the “Non-GAAP Financial Measures” section of this release
for a reconciliation of Adjusted EPS to EPS and Adjusted EBITDA to
Net Income Attributable to Ultralife Corporation.
About Ultralife Corporation
Ultralife Corporation serves its markets with
products and services ranging from power solutions to
communications and electronics systems. Through its engineering and
collaborative approach to problem solving, Ultralife serves
government, defense and commercial customers across the globe.
Headquartered in Newark, New York, the Company's
business segments include Battery & Energy Products and
Communications Systems. Ultralife has operations in North America,
Europe and Asia. For more information, visit
www.ultralifecorporation.com.
Conference Call Information
Ultralife will hold its second quarter earnings
conference call today at 8:30 AM ET. To participate in the live
call, please dial (800) 915-4836 at least ten minutes before the
scheduled start time, identify yourself and ask for the Ultralife
call. A live webcast of the conference call will be available
to investors in the Events & Presentations section of the
Company's website at http://investor.ultralifecorporation.com. For
those who cannot listen to the live broadcast, a replay of the
webcast will be available shortly after the call at the same
location.
This press release may contain forward-looking
statements based on current expectations that involve a number of
risks and uncertainties. The potential risks and uncertainties that
could cause actual results to differ materially include the impact
of COVID-19, potential reductions in revenues from key customers,
acceptance of our new products on a global basis and uncertain
global economic conditions. The Company cautions investors not to
place undue reliance on forward-looking statements, which reflect
the Company's analysis only as of today's date. The Company
undertakes no obligation to publicly update forward-looking
statements to reflect subsequent events or circumstances. Further
information on these factors and other factors that could affect
Ultralife’s financial results is included in Ultralife’s Securities
and Exchange Commission (SEC) filings, including the latest Annual
Report on Form 10-K.
ULTRALIFE CORPORATION AND SUBSIDIARIES |
CONSOLIDATED BALANCE SHEETS(Dollars in
Thousands) |
(Unaudited) |
ASSETS |
|
|
|
|
|
June 30,2021 |
|
December 31,2020 |
Current
Assets: |
|
|
|
Cash |
$15,828 |
|
$10,653 |
Trade Accounts Receivable, Net |
18,712 |
|
21,054 |
Inventories, Net |
27,414 |
|
28,193 |
Prepaid Expenses and Other Current Assets |
2,351 |
|
4,596 |
Total Current Assets |
64,305 |
|
64,496 |
|
|
|
|
Property, Plant
and Equipment, Net |
22,720 |
|
22,850 |
Goodwill |
27,115 |
|
27,018 |
Other Intangible
Assets, Net |
8,936 |
|
9,209 |
Deferred Income
Taxes, Net |
11,459 |
|
11,836 |
Other Non-Current
Assets |
1,985 |
|
2,292 |
|
|
|
|
Total Assets |
$136,520 |
|
$137,701 |
|
LIABILITIES AND SHAREHOLDERS' EQUITY |
Current Liabilities: |
|
|
Accounts Payable |
$9,545 |
|
$10,839 |
Current Portion of Long-Term Debt, Net |
624 |
|
1,361 |
Accrued Compensation and Related Benefits |
1,396 |
|
1,748 |
Accrued Expenses and Other Current Liabilities |
3,966 |
|
4,758 |
Total Current Liabilities |
15,531 |
|
18,706 |
Deferred Income
Taxes |
492 |
|
515 |
Other Non-Current
Liabilities |
1,260 |
|
1,557 |
Total Liabilities |
17,283 |
|
20,778 |
|
|
|
|
Shareholders'
Equity: |
|
|
|
Common Stock |
2,047 |
|
2,037 |
Capital in Excess of Par Value |
186,138 |
|
185,464 |
Accumulated Deficit |
(46,116) |
|
(47,598) |
Accumulated Other Comprehensive Loss |
(1,586) |
|
(1,782) |
Treasury Stock |
(21,388) |
|
(21,321) |
Total Ultralife Equity |
119,095 |
|
116,800 |
Non-Controlling
Interest |
142 |
|
123 |
Total Shareholders’ Equity |
119,237 |
|
116,923 |
|
|
|
|
Total Liabilities and Shareholders' Equity |
$136,520 |
|
$137,701 |
ULTRALIFE CORPORATION AND SUBSIDIARIES |
CONSOLIDATED STATEMENTS OF INCOME |
(In Thousands Except Per Share Amounts) |
(Unaudited) |
|
|
|
|
|
|
|
|
|
Three-Month Period Ended |
|
Six-Month Period Ended |
|
June 30, |
|
June 30, |
|
June 30, |
|
June 30, |
|
2021 |
|
2020 |
|
2021 |
|
2020 |
Revenues: |
|
|
|
|
|
|
|
Battery & Energy Products |
$22,875 |
|
$24,036 |
|
$44,986 |
|
$44,797 |
Communications Systems |
3,895 |
|
4,524 |
|
7,757 |
|
9,577 |
Total Revenues |
26,770 |
|
28,560 |
|
52,743 |
|
54,374 |
|
|
|
|
|
|
|
|
Cost of Products
Sold: |
|
|
|
|
|
|
|
Battery & Energy Products |
16,859 |
|
18,010 |
|
33,534 |
|
33,455 |
Communications Systems |
2,644 |
|
2,587 |
|
4,964 |
|
5,622 |
Total Cost of Products Sold |
19,503 |
|
20,597 |
|
38,498 |
|
39,077 |
|
|
|
|
|
|
|
|
Gross Profit |
7,267 |
|
7,963 |
|
14,245 |
|
15,297 |
|
|
|
|
|
|
|
|
Operating
Expenses: |
|
|
|
|
|
|
|
Research and Development |
1,853 |
|
1,275 |
|
3,500 |
|
2,823 |
Selling, General and Administrative |
4,323 |
|
4,394 |
|
8,702 |
|
8,695 |
Total Operating Expenses |
6,176 |
|
5,669 |
|
12,202 |
|
11,518 |
|
|
|
|
|
|
|
|
Operating
Income |
1,091 |
|
2,294 |
|
2,043 |
|
3,779 |
|
|
|
|
|
|
|
|
Other
Expense |
21 |
|
117 |
|
77 |
|
209 |
Income Before Income
Tax Provision |
1,070 |
|
2,177 |
|
1,966 |
|
3,570 |
|
|
|
|
|
|
|
|
Income Tax Provision |
248 |
|
499 |
|
465 |
|
818 |
|
|
|
|
|
|
|
|
Net
Income |
822 |
|
1,678 |
|
1,501 |
|
2,752 |
|
|
|
|
|
|
|
|
Net Income Attributable to
Non-Controlling Interest |
11 |
|
20 |
|
19 |
|
35 |
|
|
|
|
|
|
|
|
Net Income
Attributable to Ultralife Corporation |
$811 |
|
$1,658 |
|
$1,482 |
|
$2,717 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income Per Share Attributable to Ultralife Common
Shareholders – Basic |
$.05 |
|
$.10 |
|
$.09 |
|
$.17 |
|
|
|
|
|
|
|
|
Net Income Per Share Attributable to Ultralife Common
Shareholders – Diluted |
$.05 |
|
$.10 |
|
$.09 |
|
$.17 |
|
|
|
|
|
|
|
|
Weighted Average
Shares Outstanding – Basic |
16,019 |
|
15,882 |
|
15,997 |
|
15,880 |
|
|
|
|
|
|
|
|
Weighted Average
Shares Outstanding – Diluted |
16,260 |
|
16,133 |
|
16,194 |
|
16,114 |
Non-GAAP Financial Measures:
Adjusted Earnings Per Share
In evaluating our business, we consider and use
Adjusted EPS, a non-GAAP financial measure, as a supplemental
measure of our business performance in addition to GAAP financial
measures. We define Adjusted EPS as net income attributable to
Ultralife Corporation excluding the provision for deferred taxes
divided by our weighted average shares outstanding on both a basic
and diluted basis. We believe that this information is useful in
providing period-to-period comparisons of our results by reflecting
the portion of our tax provision that we expect will be offset by
our U.S. net operating loss carryforwards and other tax credits for
the foreseeable future. We reconcile Adjusted EPS to EPS, the most
comparable financial measure under GAAP. Neither current nor
potential investors in our securities should rely on Adjusted EPS
as a substitute for any GAAP measures and we encourage investors to
review the following reconciliation of Adjusted EPS to EPS and net
income attributable to Ultralife Corporation.
ULTRALIFE CORPORATION AND SUBSIDIARIES |
CALCULATION OF ADJUSTED EPS |
(In Thousands Except Per Share Amounts) |
(Unaudited) |
|
Three-Month Period Ended |
|
June 30, 2021 |
|
June 30, 2020 |
|
Amount |
|
Per Basic Share |
|
Per Diluted Share |
|
Amount |
|
Per Basic Share |
|
Per Diluted Share |
Net Income |
$811 |
|
$.05 |
|
$.05 |
|
$1,658 |
|
$.10 |
|
$.10 |
Deferred Tax Provision |
177 |
|
.01 |
|
.01 |
|
391 |
|
.03 |
|
.03 |
Adjusted Net Income |
$988 |
|
$.06 |
|
$.06 |
|
$2,049 |
|
$.13 |
|
$.13 |
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average Shares
Outstanding |
|
|
16,019 |
|
16,260 |
|
|
|
15,882 |
|
16,133 |
|
Six-Month Period Ended |
|
June 30, 2021 |
|
June 30, 2020 |
|
Amount |
|
Per Basic Share |
|
Per Diluted Share |
|
Amount |
|
Per Basic Share |
|
Per Diluted Share |
Net Income |
$1,482 |
|
$.09 |
|
$.09 |
|
$2,717 |
|
$.17 |
|
$.17 |
Deferred Tax Provision |
345 |
|
.02 |
|
.02 |
|
633 |
|
.04 |
|
.04 |
Adjusted Net Income |
$1,827 |
|
$.11 |
|
$.11 |
|
$3,350 |
|
$.21 |
|
$.21 |
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average Shares
Outstanding |
|
|
15,997 |
|
16,194 |
|
|
|
15,880 |
|
16,114 |
Adjusted EBITDA
In evaluating our business, we consider and use
Adjusted EBITDA, a non-GAAP financial measure, as a supplemental
measure of our operating performance in addition to GAAP financial
measures. We define Adjusted EBITDA as net income attributable to
Ultralife Corporation before net interest expense, provision
(benefit) for income taxes, depreciation and amortization, and
stock-based compensation expense, plus/minus expense/income that we
do not consider reflective of our ongoing continuing operations. We
reconcile Adjusted EBITDA to net income attributable to Ultralife
Corporation, the most comparable financial measure under GAAP.
Neither current nor potential investors in our securities should
rely on Adjusted EBITDA as a substitute for any GAAP measures and
we encourage investors to review the following reconciliation of
Adjusted EBITDA to net income attributable to Ultralife
Corporation.
ULTRALIFE CORPORATION AND SUBSIDIARIES |
CALCULATION OF ADJUSTED EBITDA |
(Dollars in Thousands) |
(Unaudited) |
|
Three-Month Period Ended |
|
Six-Month Period Ended |
|
June 30, 2021 |
|
June 30, 2020 |
|
June 30, 2021 |
|
June 30, 2020 |
|
|
|
|
|
|
|
|
Net Income Attributable to
Ultralife Corporation |
$811 |
|
$1,658 |
|
$1,482 |
|
$2,717 |
Adjustments: |
|
|
|
|
|
|
|
Interest and Financing Expense, Net |
55 |
|
106 |
|
111 |
|
280 |
Income Tax Provision |
248 |
|
499 |
|
465 |
|
818 |
Depreciation Expense |
730 |
|
582 |
|
1,460 |
|
1,161 |
Amortization Expense |
156 |
|
158 |
|
310 |
|
319 |
Stock-Based Compensation Expense |
186 |
|
304 |
|
370 |
|
534 |
Adjusted EBITDA |
$2,186 |
|
$3,307 |
|
$4,198 |
|
$5,829 |
Company Contact: |
Investor Relations Contact: |
Ultralife Corporation |
LHA |
Philip A.
Fain |
Jody
Burfening |
(315)
210-6110 |
(212)
838-3777 |
pfain@ulbi.com |
jburfening@lhai.com |
Ultralife (NASDAQ:ULBI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ultralife (NASDAQ:ULBI)
Historical Stock Chart
From Sep 2023 to Sep 2024